Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals

Renate T de Jongh 1, Paul Lips 1, Natasja M van Schoor 2, Kelly J Rijs 2, Dorly J H Deeg 2, Hannie C Comijs 2,3, Mark H H Kramer 1, Jan P Vandenbroucke 4 and Olaf M Dekkers 4,5

1Department of Internal Medicine and Endocrinology, 2EMGO Institute for Health and Care Research and 3Department of Psychiatry, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands and Departments of 4Clinical Epidemiology, and 5Endocrine and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands

(Correspondence should be addressed to R T de Jongh; Email: rt.dejongh@vumc.nl)

Abstract

Objective: To what extent endogenous subclinical thyroid disorders contribute to impaired physical and cognitive function, depression, and mortality in older individuals remains a matter of debate.

Design: A population-based, prospective cohort of the Longitudinal Aging Study Amsterdam.

Methods: TSH and, if necessary, thyroxine and triiodothyronine levels were measured in individuals aged 65 years or older. Participants were classified according to clinical categories of thyroid function. Participants with overt thyroid disease or use of thyroid medication were excluded, leaving 1219 participants for analyses. Outcome measures were physical and cognitive function, depressive symptoms (cross-sectional), and mortality (longitudinal).

Results: Sixty-four (5.3%) individuals had subclinical hypothyroidism and 34 (2.8%) individuals had subclinical hyperthyroidism. Compared with euthyroidism (n = 1121), subclinical hypo- and hyperthyroidism were not significantly associated with impairment of physical or cognitive function, or depression. On the contrary, participants with subclinical hypothyroidism did less often report more than one activity limitation (odds ratio 0.44, 95% confidence interval (CI) 0.22–0.86). After a median follow-up of 10.7 years, 601 participants were deceased. Subclinical hypo- and hyper-thyroidism were not associated with increased overall mortality risk (hazard ratio 0.89, 95% CI 0.59–1.35 and 0.69, 95% CI 0.40–1.20 respectively).

Conclusions: This study does not support disadvantageous effects of subclinical thyroid disorders on physical or cognitive function, depression, or mortality in an older population.
Subjects and methods

Participants and mortality

Data for this analysis was collected within the framework of the Longitudinal Aging Study Amsterdam (LASA), an ongoing cohort study in The Netherlands, which has been described previously (24). Briefly, a random sample of 3107 individuals (aged 55–85 years) participated. At baseline (1992–1993) and every 3 years subsequently a cycle of measurements was carried out. Blood samples for TSH were obtained only in 1995–1996. For financial reasons, TSH was determined in a subset of 1509 participants aged 65 years or older as of January 1, 1996. Older participants were selected because the initial aim was to examine associations of thyroid function with several outcome measures and older individuals demonstrate a higher prevalence of thyroid disorders. Participants without a blood sample or with an insufficient blood sample (n = 239) were excluded, leading to 1270 participants with TSH measurements of which over 99% were Caucasian. The study was approved by the Medical Ethics Committee of the VU University Medical Center, and informed consent was obtained from all participants.

Whether or not death had occurred on June 1, 2007, was determined by collecting data from the registries of the municipalities. The primary causes of death were obtained from the Dutch Central Bureau of Statistics and coded according to the International Classification of Diseases, 10th Revision. Mortality from cardiovascular diseases included deaths due to hypertensive disease (codes I10–I13), ischemic heart disease (codes I20–I25), arrhythmia (codes I44–I49), heart failure (code I50), cerebrovascular disease (codes I60–I69), or atherosclerosis or other diseases of the arteries (codes I70–I78).

Thyroid function

Morning whole blood samples were collected and centrifuged in 1995–1996. Serum was kept frozen until TSH determination in 2001 in the Endocrinological Laboratory of the VU University Medical Center. Subjects were allowed to eat toast and drink tea but no dairy products. In ~30% of the study population TSH was also determined immediately to obtain reference values for the local laboratory. These results were communicated to general practitioners and not used in the present analyses. TSH was measured by RIA (Centaur, Bayer Diagnostics) with an interassay co-efficient of variation (CV) of 6%. If TSH was not within the normal range, free thyroxine (T4) was measured by a competitive immunoassay (Centaur, Bayer Diagnostics) with an interassay CV of 7%. If T4 was normal in the presence of an abnormal value of TSH, free triiodothyronine (T3) was also measured. Information on the use of levothyroxine (LT4) or antithyroid medication was self-reported and accompanied by visual inspection of every container of medication available in the participant’s house. This information was obtained at the time of the blood sampling for TSH measurement in 1995–1996 and every 3 years thereafter.

Thyroid function was classified according to the clinical classification (2). Subclinical hypo- and hyperthyroidism were defined as normal T4 and T3 levels (11–22 and 3.5–6.5 pmol/l respectively) together with TSH levels, respectively, above (>4.5 mU/l) and below (<0.3 mU/l) normal values. Euthyroidism was defined by normal TSH values (≥0.3 and ≤4.5 mU/l). In three participants with abnormal TSH values T4 could not be determined and in two participants with abnormal TSH and normal T4 values T3 could not be determined. Thus, 1265 participants could be classified according to clinical categories of thyroid function. We did exclude participants that did not comply with the definition of subclinical thyroid disorders or euthyroidism (n = 22) (2), because numbers within other thyroid disorder categories were too small to draw conclusions, resulting in 1243 individuals for analyses.

Physical function

Physical function was assessed in three ways. i) Total physical performance score, ii) handgrip strength, and iii) self-reported activity limitations.

Total physical performance score was the sum of three different physical performance tests performed in 1995–1996: walking, chair stand, and tandem stand tests. The description and calculation of the scores of these tests is described elsewhere (25). The scores of the three tests were added up to obtain a total score that ranged from 0 (lowest physical performance) to 12 (highest physical performance). Data on total performance score were missing in 66 participants (n = 37 abbreviated or preterm terminated interviews; n = 8 not enough room or refusal, n = 21 time not measured or test not performed for unknown reasons).

Handgrip strength was assessed using a dynamometer (Takei TKK 5001, Takei Scientific Instruments Co. Ltd, Tokyo, Japan). The maximum strength (kilograms) of two attempts of each hand was averaged. When only one hand could be used, the maximum value of that hand was used (n = 19). Handgrip measurements were missing in five participants of which two participants were handicapped at both hands.

Self-reported activity limitations were assessed with a validated questionnaire concerning the degree of difficulty with the following six activities of daily living: climbing stairs, walking 5 min outdoors without resting, getting up and sitting down in a chair, dressing and undressing oneself, using own or public transportation, and cutting one’s own toe nails (26). Participants reported a score of zero (not any difficulty) to six (difficulty with all activities). The number was dichotomized to the presence of none or one activity
limitation or the presence of two or more activity limitations (26). Two or more activity limitations are more likely to be due to an underlying disease than one activity limitation.

Cognitive function and depression

Cognition was assessed by four tests in 1995–1996: the mini-mental state examination (MMSE), the Raven’s colored progressive matrices (RCPM), the coding task (CT), and the auditory verbal learning test (AVLT).

The MMSE is a screening test for global cognitive functioning. The highest score is 30; a score of 23 or less indicates cognitive impairment (27).

The RCPM is used to measure a person’s ability for nonverbal and abstract reasoning. In LASA, a short version was used because of time limitations (28). Total scores range from 0 to 24 items, a lower score indicating worse performance.

Information processing speed was measured by an adjusted version of the CT (29). The task consists of three identical trials, in which the respondent has to combine 15 sets of two characters. The total score is defined as the total number of completed characters and ranges from 0 to 45 items.

Memory was measured with an abbreviated version of the AVLT (30). The participant is asked to remember as many words (of 15 nouns) as possible in three trials with an identical word list. The total number remembered is a measure of immediate memory and ranges from 0 to 45. In addition, the amount remembered after a 20 min interval is a measure of delayed memory. This is expressed as the percentage of the maximum number remembered during any of the earlier trials and ranges from 0 to more than 100%.

Depression was assessed using the Center for Epidemiologic Studies-Depression Scale (CES-D). Total score ranges from 0 to 60, a higher score indicating more depressive symptoms. The cut off point for depressive symptoms (CES-D ≥16) was pre-established and validated in The Netherlands (31).

Data of the cognitive function tests and depression were missing for several reasons (MMSE, n = 2; RCPM, n = 58; CT, n = 58; AVLT, n = 25; and CESD, n = 38): an abbreviated interview, preterm termination, too many missing items, physical problems, technical problems, or the cognitive incapability to understand and/or perform the test. In 29 participants at least one of the tests was not performed because of inability to understand and/or perform the given instructions. We performed analyses with the allocation of a score of zero to these missing test results to examine the contribution of this group.

Covariates

We identified the following potential confounders: alcohol use, smoking status, educational level, number of chronic diseases, BMI, mean arterial pressure (MAP), heart rate, total cholesterol, and physical activity. In addition, BMI is identified as a potential mediator in the relationship between thyroid disorders and physical function. Also, BMI, heart rate, MAP, and total cholesterol are potential mediators in the relationship between thyroid disorders and mortality. The choice of potential confounders and mediators was based on associations with thyroid function and outcome measures, either in our study or in the literature.

Smoking status, alcohol consumption (32), educational level, and the number of chronic diseases (pulmonary disease, cardiac disease, diabetes mellitus, cancer, stroke, arthritis, and peripheral atherosclerosis) was assessed by self-report. Physical activity was assessed with the LASA Physical Activity Questionnaire (LAPAQ) which is described elsewhere (33). Physical activity was not assessed in 37 participants with an abbreviated or preterm terminated interview. Data on educational level, alcohol use, chronic diseases, BMI, MAP, heart rate, and total cholesterol were missing in 2, 1, 1, 22, 26, 26, and 31 participants, respectively mostly due to logistic or technical reasons.

Statistical analysis

Differences in baseline characteristics were tested using one-way ANOVA (normally distributed continuous variables), the Kruskal–Wallis H test (skewed continuous variables), and the χ² test (categorical variables).

Logistic and linear regression analyses were used to analyze associations of categories of thyroid function with dichotomous and continuous outcome variables respectively. Cox’s proportional hazard model was used to study effects on mortality. The category euthyroidism served as the reference group for all analyses. All analyses were adjusted for age and gender (model 1). In addition, we constructed a model with possible confounders and/or mediators for the separate outcome variables (model 2). In all analyses, the maximum number of complete cases was included.

We chose to present analyses with thyroid function classified in clinical categories and not in percentiles for two reasons. First, this classification is the most appropriate to address the objective of the study, which was to examine associations between subclinical thyroid disorders and outcome measures. Second, the use of percentiles may create TSH categories that are overly broad, which may mask true effects of TSH (34).

Results

Baseline characteristics and thyroid status

Participants who used LT₄ or antithyroid medication in 1995–1996 were excluded from the cross-sectional analyses (n = 24), resulting in 1219 individuals for cross-sectional analyses. Mean age of the participants
studied for cross-sectional analyses was 75.5±6.6 years. Gender was almost equally distributed (50.5% female). The median TSH was 1.5 mU/l (interquartile range: 1.0–2.3). Thyroid function was normal in 1121 participants (92.0%). Sixty-four (5.3%) participants had subclinical hypothyroidism and 34 (2.8%) participants had subclinical hyperthyroidism. Of the participants with subclinical hypothyroidism 14 (21.9%) had a TSH above 10.0 mU/l and of the participants with subclinical hyperthyroidism 13 (38.2%) had a TSH below 0.10 mU/l. Baseline characteristics of the sample studied for cross-sectional analyses stratified by thyroid categories are presented in Table 1.

**Physical function**

Table 2 shows results of physical outcome measures according to thyroid categories. Compared with euthyroidism, subclinical hypo- and hyper-thyroidism were not related to differences in total physical performance score. Of the separate physical performance tests, subclinical hyperthyroidism was associated with a higher score on the tandem stand test after correction for potential confounders (β = 1.45, 95% confidence interval (CI) 0.08–2.81, P = 0.037). Results of other physical performance tests did not differ between participants with subclinical thyroid disorders and euthyroidism.

Participants with subclinical hyperthyroidism had lower mean handgrip strength than euthyroid participants, although this difference did not reach statistical significance. Subclinical hypo- and hyper-thyroidism were not associated with a higher amount of self-reported activity limitations. On the contrary, participants with subclinical hypothyroidism did less often report more than one activity limitation. When activity limitations were analyzed as a continuous variable there were no significant differences between the thyroid categories (subclinical hypothyroidism versus euthyroidism, β = −0.05, 95% CI −0.12–0.02, P = 0.19 and subclinical hyperthyroidism versus euthyroidism, β = −0.31, 95% CI −0.81–0.21, P = 0.24).

**Cognitive function and depression**

Global cognitive function and depressive symptoms according to thyroid categories are presented in Table 3. Subclinical hypo- and hyper-thyroidism were not related to a higher prevalence of impaired global cognitive function or depression. Similar results were obtained when MMSE and CES-D were analyzed as continuous variables by linear regression analyses (data not shown).

Results for the separate cognitive function tests are shown in Table 4. None of the thyroid categories were associated with limitations in cognitive function tests.

Additional analyses with allocation of a score of zero to participants, who were not able to perform a test because they were not able to understand or perform the instructions, did not materially influence our results.

**Mortality**

Participants who started with LT₄ or antithyroid medication during follow-up were excluded for the

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Baseline characteristics of participants studied for cross-sectional analyses stratified by clinical thyroid categories. Data are presented as mean ± S.D., median (interquartile range) or n (%) as appropriate.</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>Subclinical hypothyroidism</td>
</tr>
<tr>
<td>Female (%)</td>
<td>64 (5.3)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>74.9±6.8</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.1±4.8 (n=63)†</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>109.5±16.7 (n=62)</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>69.7±11.0 (n=62)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>6.3±1.1 (n=63)</td>
</tr>
<tr>
<td>TSH (mU/l)</td>
<td>6.89 (5.6–9.59)†</td>
</tr>
<tr>
<td>Alcohol consumption</td>
<td>Non drinker</td>
</tr>
<tr>
<td></td>
<td>Light drinker</td>
</tr>
<tr>
<td></td>
<td>Moderate drinker</td>
</tr>
<tr>
<td></td>
<td>(Very) excessive drinker</td>
</tr>
<tr>
<td>Smoking</td>
<td>Never</td>
</tr>
<tr>
<td></td>
<td>Former</td>
</tr>
<tr>
<td></td>
<td>Current</td>
</tr>
<tr>
<td>Education (year)</td>
<td>8.0±3.4†</td>
</tr>
<tr>
<td>Physical activity (min/day)</td>
<td>172.0±103.2 (n=62)†</td>
</tr>
<tr>
<td>No. of chronic diseases (0–7)</td>
<td>1.0 (1.0–2.0)</td>
</tr>
</tbody>
</table>

*P<0.06, †P<0.05, ‡P<0.01, and §P<0.001 versus euthyroidism.
Table 2  Physical performance, handgrip strength, and activity limitations according to different clinical thyroid categories. A higher total physical performance score indicates better physical performance. A higher handgrip strength indicates stronger muscles. A higher score on activity limitations indicates more self-reported activity limitations. Mean ± s.d. and n (%) are depicted for the number included in Model 1. Model 1 is adjusted for age and gender. Model 2 is adjusted for age, gender, alcohol use, smoking, number of chronic diseases, physical activity, and body mass index (BMI).

<table>
<thead>
<tr>
<th></th>
<th>Subclinical hypothyroidism</th>
<th>Subclinical hyperthyroidism</th>
<th>Euthyroidism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total performance score (range 0–12)</td>
<td>7.5 ± 3.2</td>
<td>7.7 ± 2.7</td>
<td>7.5 ± 3.1</td>
</tr>
<tr>
<td>Model 1, β (95% CI)</td>
<td>0 (–0.1–0.1; n = 62)</td>
<td>0.6 (–0.4–1.6; n = 28)</td>
<td>Reference (n = 1065)</td>
</tr>
<tr>
<td>Model 2, β (95% CI)</td>
<td>0 (–0.1–0.2; n = 62)</td>
<td>0.5 (–0.4–1.5; n = 28)</td>
<td>Reference (n = 1056)</td>
</tr>
<tr>
<td>Handgrip strength (kg; range 0–64)</td>
<td>28.3 ± 9.2</td>
<td>26.3 ± 8.7</td>
<td>Reference (n = 1197)</td>
</tr>
<tr>
<td>Model 1, β (95% CI)</td>
<td>0.2 (–0.1–0.5; n = 63)</td>
<td>–1.5 (–3.6–0.6; n = 34)</td>
<td>Reference (n = 1119)</td>
</tr>
<tr>
<td>Model 2, β (95% CI)</td>
<td>0.2 (–0.1–0.5; n = 61)</td>
<td>–1.9 (–3.9–0.2; n = 31)</td>
<td>Reference (n = 1081)</td>
</tr>
<tr>
<td>Activity limitations (&gt;1 vs ≤1 item)</td>
<td>19 (29.7)</td>
<td>9 (27.3)</td>
<td>402 (36.2)</td>
</tr>
<tr>
<td>Model 1, OR (95% CI)</td>
<td>0.63 (0.35–1.14; n = 64)</td>
<td>Reference (n = 1086)</td>
<td></td>
</tr>
<tr>
<td>Model 2, OR (95% CI)</td>
<td>0.44 (0.22–0.86; n = 62)</td>
<td>Reference (n = 1064)</td>
<td></td>
</tr>
</tbody>
</table>

*p < 0.09, †p < 0.08, and ‡p < 0.05 versus euthyroidism.

Subclinical thyroid disorders

longitudinal analyses (n = 20, six in the euthyroid category, 13 in the subclinical hypothyroid category, and one in the subclinical hyperthyroid category). Data whether or not death had occurred from the registers of the municipalities were not available for two euthyroid participants, resulting in 1197 individuals for analysis of mortality. Baseline characteristics did not differ between the sample studied for longitudinal analyses and the sample studied for cross-sectional analyses (data not shown).

During a median 10.7 years of follow-up (inter-quartile range 5.6–11.2 years), 601 deaths occurred (50.2%) of which 184 due to cardiovascular causes. Of the 184 deaths to cardiovascular disease, 51 (27.7%) deaths occurred due to ischemic heart disease (one participant with subclinical hypothyroidism and three participants with subclinical hyperthyroidism). Hazard ratio’s of all-cause and cardiovascular mortality according to thyroid categories are presented in Table 5 and Kaplan–Meier mortality curves for different thyroid categories are depicted in Fig. 1. The all-cause and cardiovascular mortality risk did not significantly differ between the subclinical thyroid categories and euthyroidism. BMI, cholesterol, heart rate, and MAP were identified as potential mediators of the relationship between subclinical thyroid disease and mortality. Additional analyses demonstrated only minimal changes in hazard ratio (<10%) after adjustment for potential mediators separately or combined (data not shown).

Sensitivity analyses were performed after inclusion of participants on thyroid medication at baseline (n = 24) and during follow-up (n = 20) resulting in analyses of data of 1243 participants for cross-sectional analyses and 1241 participants for longitudinal analyses. This did not materially change the effect estimates (data not shown).

Discussion

The present findings demonstrated that endogenous subclinical thyroid dysfunction was not associated with impaired physical or cognitive function, or depression...
in a Dutch cohort aged 65 years and older. If anything, the presence of in particular subclinical hypothyroidism might have been related to a slight advantageous effect on self-reported activity limitations. In addition, both subclinical thyroid disorders were not related to an increased risk of mortality during a follow-up of more than 10 years.

**Strengths and limitations**

The strengths of this study are the population-based design which enhances generalizability (35). A second strength is the detailed information on physical and cognitive functioning provided by various validated tests. A limitation is that all outcome measures except mortality were analyzed in a cross-sectional way, which cannot exclude cohort effects. In addition, the absence of longitudinal TSH, free T4 and T3 measurements may have contributed to misclassification. However, the physical function tests were performed within a short time interval from TSH measurement. Therefore, it is likely that the measured TSH reflects the thyroid function at time of test performances. However, effects of misclassification and the development of thyroid disorders during follow-up might have affected associations with mortality. In a ~70% of the participants TSH was determined only 5–6 years after blood sampling and for that reason these measurements did not influence the course of the thyroid disorders and treatment decisions of primary care physicians. Regarding the 30% of the study

### Table 4 Specific cognitive function tests according to different clinical thyroid categories. Mean ± s.d. are depicted for the number included in Model 1. Model 1 is adjusted for age and gender. Model 2 is adjusted for age, gender, alcohol use, smoking status, educational level, number of chronic diseases, and physical activity.

<table>
<thead>
<tr>
<th></th>
<th>Subclinical hypothyroidism</th>
<th>Subclinical hyperthyroidism</th>
<th>Euthyroidism</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCPM (number of items; range 1–24)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± s.d.</td>
<td>17.5 ± 4.0</td>
<td>16.7 ± 4.7</td>
<td>17.5 ± 4.0</td>
</tr>
<tr>
<td>Model 1, β (95% CI)</td>
<td>0 (–0.2–0.2; n = 61)</td>
<td>0.1 (–0.1–0.3; n = 61)</td>
<td>Reference (n = 1072)</td>
</tr>
<tr>
<td>Model 2, β (95% CI)</td>
<td>0.1 (–0.1–0.3; n = 61)</td>
<td>0.3 (–1.6–1.0; n = 29)</td>
<td>Reference (n = 1064)</td>
</tr>
<tr>
<td>CT (number of digits; range 4–45)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± s.d.</td>
<td>24.8 ± 8.0</td>
<td>23.9 ± 7.7</td>
<td>25.5 ± 7.5</td>
</tr>
<tr>
<td>Model 1, β (95% CI)</td>
<td>−0.1 (–0.4–0.3; n = 63)</td>
<td>0.3 (–2.7–2.1; n = 31)</td>
<td>Reference (n = 1095)</td>
</tr>
<tr>
<td>Model 2, β (95% CI)</td>
<td>0.1 (–0.2–0.4; n = 62)</td>
<td>0.2 (–2.0–2.4; n = 28)</td>
<td>Reference (n = 1065)</td>
</tr>
<tr>
<td>AVLT immediate recall (number of words; range 0–42)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± s.d.</td>
<td>18.7 ± 6.1</td>
<td>18.2 ± 5.1</td>
<td>19.2 ± 6.4</td>
</tr>
<tr>
<td>Model 1, β (95% CI)</td>
<td>−0.3 (–0.6–0.1; n = 63)</td>
<td>−0.1 (–2.1–1.9; n = 33)</td>
<td>Reference (n = 1104)</td>
</tr>
<tr>
<td>Model 2, β (95% CI)</td>
<td>−0.2 (–0.5–0.1; n = 62)</td>
<td>−0.1 (–2.0–1.7; n = 30)</td>
<td>Reference (n = 1073)</td>
</tr>
<tr>
<td>AVLT delayed recall (%; range 0–160)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± s.d.</td>
<td>72 ± 25</td>
<td>63 ± 26</td>
<td>67 ± 26</td>
</tr>
<tr>
<td>Model 1, β (95% CI)</td>
<td>0.5 (–0.8–1.8; n = 63)</td>
<td>1.1 (–9.8–7.4; n = 33)</td>
<td>Reference (n = 1097)</td>
</tr>
<tr>
<td>Model 2, β (95% CI)</td>
<td>0.5 (–0.7–1.8; n = 62)</td>
<td>0.2 (–9.8–6.6; n = 33)</td>
<td>Reference (n = 1068)</td>
</tr>
</tbody>
</table>

RCPM, Raven’s colored progressive matrices; CT, coding task; AVLT, auditory verbal learning test.
population in which general practitioners were informed about thyroid function at baseline, we did have data on medication and excluded participants who started thyroid medication during follow-up. However, we lacked information on other treatment modalities such as radioactive iodine or surgery and a direct effect of these treatments on study outcomes and in particular mortality cannot be excluded. In addition, although we adjusted the analysis for a number of comorbidities, residual confounding cannot be ruled out with certainty. Also, our dataset contained a number of missing data and we included only complete cases in the analyses. Part of the data is missing due to technical and logistic reasons and can be assumed to be missing completely at random. However, other data, in particular of physical and cognitive function tests, may be missing not completely at random and thus influence the outcomes. Finally, it should be emphasized that the power of our study to detect small differences in outcomes between subclinical thyroid disorders and euthyroidism was limited. The sample size of this study was in fact predefined, meaning that the data were already available for research purposes as is often the case with observational studies. Since there were 34 patients with subclinical hyperthyroidism and 64 patients with subclinical hypothyroidism, the study was adequately powered to give meaningful estimates for continuous outcomes. As can be seen from Tables 2 and 4, the CI accompanying the calculated effect estimates are rather small, showing that for continuous outcomes our study provides estimates with sufficient precision to be meaningful. However, for binary outcomes, such as mortality, the power will be lower, and negative findings should be interpreted with more caution.

Physical function

In this study, participants with subclinical thyroid disorders demonstrated similar physical performance as euthyroid participants. Moreover, subclinical thyroid disorders, in particular subclinical hypothyroidism, might even be related to a slight benefit in self-reported activity limitations. This is in agreement with a recent study in a population of similar age, which demonstrated no differences in walking ability between subclinical hypothyroid and euthyroid participants. These data even suggested a slight functional advantage in those with mild TSH elevations (3). In addition, elevated TSH was not associated with impairment of activities of daily living in the Leiden 85-plus study (12). Although impaired muscle strength is a frequent finding in overt hypothyroidism (36), subclinical hypothyroidism is not related to impaired muscle strength in our or other previous studies (8, 37). Our results did not exclude a negative effect of subclinical hyperthyroidism on muscle strength. Previously, decreased muscle strength in subclinical hyperthyroidism has been found in proximal muscle groups of the leg (8). In our study, however, the potential impairment of muscle strength in subclinical hyperthyroidism was small and did not coincide with impairments of physical performance or daily functioning. Earlier studies have shown similar exercise performance (7) or arm-hand coordination (4) in individuals with subclinical hyperthyroidism and euthyroidism. Therefore, our findings and earlier studies may suggest that the clinical impact of lower muscle strength in subclinical hyperthyroidism, if present at all, is limited.

Cognitive function and depression

In our study, subclinical thyroid disorders were not related to impairment in any of the tested domains of cognitive function or to more depressive symptoms. Although cognitive impairment in subclinical hypothyroidism has been shown in studies in populations with a mean age under 65 years (9, 10), our results are in line with most (11, 38, 39) but not all (40, 41) studies in populations aged 65 years and older. In addition, studies in younger age groups have shown a clear beneficial effect of LT 4 supplementation on cognitive function (10). A recent study in individuals aged 65 years and older, however, did not show such positive effects (13). Studies in older populations examining associations between subclinical hyperthyroidism and cognitive function are scarce. Our results are in line with a large cross-sectional study performed in the UK (38), which also did not demonstrate a relationship, but they contrast with a recent Italian study which showed that subclinical hyperthyroidism was associated with lower MMSE scores (9). This difference may be partly explained by differences in study populations, as the mean MMSE in the latter study was much lower than in
our study population. Our study also confirms the findings of other studies in which no association was found between subclinical thyroid disorders and depression (42).

Mortality

Previous meta-analyses show conflicting results on the association of subclinical hyperthyroidism and all-cause mortality (14, 16–18). In addition, studies published after these meta-analyses show a similar diversity in results (43–45). This ambiguity in findings may reflect differences in study populations, definitions of subclinical hyperthyroidism, adjustment for potential confounders, duration of follow-up, and presence of comorbidities (1, 45). Our population-based cohort study demonstrated that subclinical hyperthyroidism, in contrast to overt thyroid disorders, was not related to increased all-cause mortality risk. This is in line with three other population-based studies in a similar age group (19, 21, 22). In contrast, a TSH < 0.5 mU/l compared with TSH ≥ 0.5 mU/l was associated with increased all-cause mortality in a population of 60 years and older (23). However, in that study, participants with an elevated TSH were included in the reference category. An additional analysis of our data using a similar reference category (TSH ≥ 0.5 mU/l) resulted in a hazard ratio for all-cause mortality of 1.17 (95% CI 0.81–1.71). Further, the relationship was found for a follow-up time of 2–5 years, but not for the total follow-up time of 10 years, which the authors explained by the high amount of deceased participants at the end of the study. The Kaplan–Meier mortality curves of our data demonstrate that even in a shorter follow-up time subclinical hyperthyroidism is not likely to be associated with increased all-cause mortality risk.

Although meta-analyses examining the relationship between subclinical hypothyroidism and all-cause mortality also show disagreement on the presence or absence of a relationship (14–18), all studies in populations aged over 60 years (19–23) are in agreement with our study and demonstrate the absence of significant relationships between subclinical hypothyroidism and all-cause mortality. In addition, a recent meta-analysis based on individual data analyses demonstrated a small but not significant increased risk of all-cause mortality in individuals aged 65–79 years and no increased risk in individuals aged 80 years and above (15). Results from the Leiden 85-plus study suggested that in a very old population an elevation of TSH concentrations of 7 mU/ml or above (14, 15). Although our data does not suggest a relationship between subclinical thyroid disorders and increased cardiovascular mortality, the number of deaths due to cardiovascular disease and in particular coronary heart disease was too small to draw definite conclusions.

Clinical implications

Our data demonstrates the absence of relationships between subclinical thyroid disorders, on the one hand, and disadvantageous effects on physical and cognitive function, depression, or mortality, on the other hand. In older populations screening for thyroid disorders is often performed by primary care physicians, internists and geriatricians in the presence of physical or cognitive impairments, or depressive symptoms. Findings of thyroid function tests in the subclinical range may not automatically imply an explanation for the complaints and subsequent initiation of treatment. Indeed, the presence of symptoms specific for thyroid dysfunction, such as palpitations or weight loss, necessitate thyroid function testing, and may warrant treatment for subclinical thyroid disorders. However, only randomized controlled trials in large cohorts can definitely answer the question whether treatment of subclinical thyroid dysfunction will affect morbidity and mortality in older individuals.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work is based on data from the Longitudinal Aging Study Amsterdam (LASA), which is financially supported by the Dutch Ministry of Public Health, Welfare, and Sports.

Acknowledgements

The authors thank Jan Poppelaars for processing and distributing the data.

References

1 Biondi B & Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008 29 76–111. (doi:10.1210/er.2006-0043)
2 Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklin JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS & Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Journal of the American Medical Association 2004 291 228–238. (doi:10.1001/jama.291.2.228)
4 Schlote B, Nowotny B, Schaaf L, Kleinbohl D, Schmidt R, Teuber J, Paschke R, Vardarli I, Kaumeier S & Usadel KH. Subclinical...
Subclinical thyroid disorders


Impact of subclinical thyroid dysfunction in elderly patients: results of the Invecchiare in Chianti study.


Received 12 May 2011
Revised version received 30 June 2011
Accepted 18 July 2011

www.eje-online.org